News | April 14, 2010

PET Imaging Agent Identifies Patients with Alzheimers

April 14, 2010 - Researchers found a new amyloid imaging agent for positron emission tomography (PET) to be efficacious in assigning patients with clinically probable Alzheimer's disease (AD) or amnestic mild cognitive impairment (MCI).
The multicenter phase II trial, Primary Outcome Analysis of the Multicentre Phase II Trial of 18F-Flutemetamol, a Pittsburgh Compound B Derivative for In Vivo Beta Amyloid Imaging, focused on 18F-Flutemetamol, a Pittsburgh compound B derivative for in vivo beta amyloid imaging. Primary outcome analysis found the agent used with PET identified patients likely to have AD or amnestic MCI. Results also showed healthy controls (HC) were at a raised versus normal uptake category.
The viability of the agent, 18F-flutemetamol PET, could augment the impact of beta amyloid imaging on research and clinical practice since its use does not require an on-site cyclotron.
In the trial, which GE Healthcare supported, there were 27 patients with early-stage AD, 20 with MCI. Fifteen had HC above and 10 below 55 years. 20 of the AD and 20 of the MCI cases also underwent a 11C-PIB PET. Five central independent readers blinded to the clinical diagnosis assigned the 18F-flutemetamol scans to either raised or normal uptake categories in a binary way on the basis of visual assessment. As a primary outcome, the researchers used clinical diagnosis as SOT to calculate sensitivity and specificity of visual assessment of AD and HC scans. They also determined concordance between visual assignment and assignment based on standardized uptake value ratios in a composite cortical region (SUVRcomp).
They found the visual assessment assigned 25/27 scans from the AD group to the raised category, 1/15 scans from the elderly HC, and 9/20 scans from the MCI group. Sensitivity and specificity with clinical diagnosis as SOT (AD vs HC) was 92.6 percent and 96 percent, respectively. The correlation coefficient between 18F flutemetamol SUVRcomp and 11C-PIB SUVRcomp was 0.94.
The researchers concluded the study met their primary outcome and supports a role for 18F-flutemetamol PET as a potential biomarker for AD-related amyloidosis.
The investigators will present the results from the study on April 16 at the 62nd American Academy of Neurology in Toronto, Canada.
For more information: www.aan.com/go/am10

Related Content

Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....